Annual report
2796.TEDINET S100UB27
Period2023-06-01 → 2024-05-31
Filed2024-08-30
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥54.5bn | 2023-06-01 → 2024-05-31 | Cons. | Net sales |
| Revenue | ¥52.0bn | 2022-06-01 → 2023-05-31 | Cons. | Net sales |
| Revenue | ¥51.6bn | 2021-06-01 → 2022-05-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥52.3bn | 2020-06-01 → 2021-05-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥51.0bn | 2019-06-01 → 2020-05-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥916m | 2023-06-01 → 2024-05-31 | Cons. | Operating income |
| Operating income | ¥1.4bn | 2022-06-01 → 2023-05-31 | Cons. | Operating income |
| Ordinary income | ¥833m | 2023-06-01 → 2024-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.4bn | 2022-06-01 → 2023-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.5bn | 2021-06-01 → 2022-05-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2020-06-01 → 2021-05-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2019-06-01 → 2020-05-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥143m | 2023-06-01 → 2024-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥1.0bn | 2022-06-01 → 2023-05-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥351m | 2023-06-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥333m | 2022-06-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥447m | 2021-06-01 → 2022-05-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥426m | 2020-06-01 → 2021-05-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥577m | 2019-06-01 → 2020-05-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥342m | 2023-06-01 → 2024-05-31 | Cons. | Profit loss |
| Net income | ¥347m | 2022-06-01 → 2023-05-31 | Cons. | Profit loss |
| Total assets | ¥29.5bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥23.4bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥23.7bn | at 2022-05-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥24.7bn | at 2021-05-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥25.2bn | at 2020-05-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥22.0bn | at 2024-05-31 | Cons. | Liabilities |
| Total liabilities | ¥16.4bn | at 2023-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.4bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥7.0bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2022-05-31d | Cons. | Net assets |
| Net assets / equity | ¥6.3bn | at 2021-05-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥5.9bn | at 2020-05-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.2bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.7bn | at 2023-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.1bn | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2023-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2022-05-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.6bn | at 2021-05-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.5bn | at 2020-05-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥2.7bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.5bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥713m | 2021-06-01 → 2022-05-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.9bn | 2020-06-01 → 2021-05-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.6bn | 2019-06-01 → 2020-05-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥3.1bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥703m | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥292m | 2021-06-01 → 2022-05-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2020-06-01 → 2021-05-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥734m | 2019-06-01 → 2020-05-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥2.8bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.1bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.0bn | 2021-06-01 → 2022-05-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥728m | 2020-06-01 → 2021-05-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥766m | 2019-06-01 → 2020-05-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-33.41 | 2023-06-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.45 | 2022-06-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥47.99 | 2021-06-01 → 2022-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥45.83 | 2020-06-01 → 2021-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥61.11 | 2019-06-01 → 2020-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥26.89 | 2022-06-01 → 2023-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥36.29 | 2021-06-01 → 2022-05-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥34.64 | 2020-06-01 → 2021-05-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥46.38 | 2019-06-01 → 2020-05-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥636.25 | at 2024-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥708.01 | at 2023-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥684.2 | at 2022-05-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥646.66 | at 2021-05-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥613.2 | at 2020-05-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 24.3% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.5% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.9% | at 2022-05-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 24.3% | at 2021-05-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.6% | at 2020-05-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | -5.1% | 2023-06-01 → 2024-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2022-06-01 → 2023-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.2% | 2021-06-01 → 2022-05-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2020-06-01 → 2021-05-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.5% | 2019-06-01 → 2020-05-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,848 | at 2024-05-31 | Cons. | Number of employees |
| Employees | 1,555 | at 2023-05-31 | Cons. | Number of employees |
| Employees | 1,544 | at 2022-05-31d | Cons. | Number of employees |
| Employees | 1,546 | at 2021-05-31d | Cons. | Number of employees |
| Employees | 1,555 | at 2020-05-31d | Cons. | Number of employees |
| Revenue | ¥1.1bn | 2023-06-01 → 2024-05-31 | Standalone | Net sales |
| Revenue | ¥1.3bn | 2022-06-01 → 2023-05-31 | Standalone | Net sales |
| Revenue | ¥1.3bn | 2021-06-01 → 2022-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.4bn | 2020-06-01 → 2021-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.2bn | 2019-06-01 → 2020-05-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥28m | 2023-06-01 → 2024-05-31 | Standalone | Operating income |
| Operating income | ¥317m | 2022-06-01 → 2023-05-31 | Standalone | Operating income |
| Ordinary income | ¥1.1bn | 2023-06-01 → 2024-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥415m | 2022-06-01 → 2023-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥406m | 2021-06-01 → 2022-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥428m | 2020-06-01 → 2021-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥378m | 2019-06-01 → 2020-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.0bn | 2023-06-01 → 2024-05-31 | Standalone | Income before income taxes |
| Profit before tax | ¥158m | 2022-06-01 → 2023-05-31 | Standalone | Income before income taxes |
| Net income | ¥1.0bn | 2023-06-01 → 2024-05-31 | Standalone | Profit loss |
| Net income | ¥82m | 2022-06-01 → 2023-05-31 | Standalone | Profit loss |
| Net income | ¥122m | 2021-06-01 → 2022-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥320m | 2020-06-01 → 2021-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥264m | 2019-06-01 → 2020-05-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥19.4bn | at 2024-05-31 | Standalone | Assets |
| Total assets | ¥14.1bn | at 2023-05-31 | Standalone | Assets |
| Total assets | ¥14.6bn | at 2022-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥14.9bn | at 2021-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥15.6bn | at 2020-05-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥12.7bn | at 2024-05-31 | Standalone | Liabilities |
| Total liabilities | ¥9.3bn | at 2023-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥6.7bn | at 2024-05-31 | Standalone | Net assets |
| Net assets / equity | ¥4.8bn | at 2023-05-31 | Standalone | Net assets |
| Net assets / equity | ¥4.8bn | at 2022-05-31d | Standalone | Net assets |
| Net assets / equity | ¥4.8bn | at 2021-05-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.6bn | at 2020-05-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2024-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥859m | at 2023-05-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥98.47 | 2023-06-01 → 2024-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥8.77 | 2022-06-01 → 2023-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥13.11 | 2021-06-01 → 2022-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥34.39 | 2020-06-01 → 2021-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.94 | 2019-06-01 → 2020-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥94.3 | 2023-06-01 → 2024-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥6.78 | 2022-06-01 → 2023-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥10.03 | 2021-06-01 → 2022-05-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥26.03 | 2020-06-01 → 2021-05-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥21.29 | 2019-06-01 → 2020-05-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥20 | 2023-06-01 → 2024-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2022-06-01 → 2023-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2021-06-01 → 2022-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2020-06-01 → 2021-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2019-06-01 → 2020-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥577.28 | at 2024-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥488.13 | at 2023-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥492.05 | at 2022-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥490.97 | at 2021-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥470.21 | at 2020-05-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 33.5% | at 2024-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.7% | at 2023-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2022-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.7% | at 2021-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.0% | at 2020-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 18.7% | 2023-06-01 → 2024-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.8% | 2022-06-01 → 2023-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.7% | 2021-06-01 → 2022-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.2% | 2020-06-01 → 2021-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.1% | 2019-06-01 → 2020-05-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 12,060,381 | at 2024-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,746,645 | at 2023-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,673,785 | at 2022-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,615,515 | at 2021-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,560,655 | at 2020-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 64 | at 2024-05-31 | Standalone | Number of employees |
| Employees | 64 | at 2023-05-31 | Standalone | Number of employees |
| Employees | 60 | at 2022-05-31d | Standalone | Number of employees |
| Employees | 33 | at 2021-05-31d | Standalone | Number of employees |
| Employees | 35 | at 2020-05-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 93
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-06-01 → 2024-05-31 | ¥134m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-06-01 → 2024-05-31 | ¥67m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-05-31 | 79 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-06-01 → 2024-05-31 | ¥834m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-06-01 → 2024-05-31 | ¥834m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-05-31 | ¥1.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-06-01 → 2024-05-31 | −¥5m |
| Reconciling Itemsreconciling | segment assets | at 2024-05-31 | ¥45m |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2024-05-31 | −¥329m |
| Cosmetic Drug And Convenience Storereportable segment | capex | 2023-06-01 → 2024-05-31 | ¥13m |
| Cosmetic Drug And Convenience Storereportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥39m |
| Cosmetic Drug And Convenience Storereportable segment | employees | at 2024-05-31 | 119 pure |
| Cosmetic Drug And Convenience Storereportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥8.3bn |
| Cosmetic Drug And Convenience Storereportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥8.3bn |
| Cosmetic Drug And Convenience Storereportable segment | segment assets | at 2024-05-31 | ¥1.8bn |
| Cosmetic Drug And Convenience Storereportable segment | segment profit | 2023-06-01 → 2024-05-31 | −¥50m |
| Custody Of Medical Documentsreportable segment | capex | 2023-06-01 → 2024-05-31 | ¥15m |
| Custody Of Medical Documentsreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥41m |
| Custody Of Medical Documentsreportable segment | employees | at 2024-05-31 | 31 pure |
| Custody Of Medical Documentsreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥664m |
| Custody Of Medical Documentsreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥664m |
| Custody Of Medical Documentsreportable segment | segment assets | at 2024-05-31 | ¥1.6bn |
| Custody Of Medical Documentsreportable segment | segment profit | 2023-06-01 → 2024-05-31 | ¥91m |
| Dispensing Pharmacyreportable segment | capex | 2023-06-01 → 2024-05-31 | ¥488m |
| Dispensing Pharmacyreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥447m |
| Dispensing Pharmacyreportable segment | employees | at 2024-05-31 | 1408 pure |
| Dispensing Pharmacyreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥44.2bn |
| Dispensing Pharmacyreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥44.2bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2024-05-31 | ¥24.1bn |
| Dispensing Pharmacyreportable segment | segment profit | 2023-06-01 → 2024-05-31 | ¥1.1bn |
| Medical Mallreportable segment | capex | 2023-06-01 → 2024-05-31 | ¥13m |
| Medical Mallreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥17m |
| Medical Mallreportable segment | employees | at 2024-05-31 | 20 pure |
| Medical Mallreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥506m |
| Medical Mallreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥506m |
| Medical Mallreportable segment | segment assets | at 2024-05-31 | ¥199m |
| Medical Mallreportable segment | segment profit | 2023-06-01 → 2024-05-31 | ¥113m |
| —segment total | capex | 2023-06-01 → 2024-05-31 | ¥530m |
| —segment total | depreciation | 2023-06-01 → 2024-05-31 | ¥546m |
| —segment total | revenue | 2023-06-01 → 2024-05-31 | ¥53.6bn |
| —segment total | revenue external | 2023-06-01 → 2024-05-31 | ¥53.6bn |
| —segment total | segment assets | at 2024-05-31 | ¥27.7bn |
| —segment total | segment profit | 2023-06-01 → 2024-05-31 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-06-01 → 2024-05-31 | ¥664m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-06-01 → 2024-05-31 | ¥613m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2024-05-31 | ¥54.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2024-05-31 | ¥54.5bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-05-31 | ¥29.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2024-05-31 | ¥1.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2022-06-01 → 2023-05-31 | ¥108m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2022-06-01 → 2023-05-31 | ¥42m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-06-01 → 2023-05-31 | ¥779m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-06-01 → 2023-05-31 | ¥779m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-05-31 | ¥2.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-06-01 → 2023-05-31 | ¥36m |
| Reconciling Itemsreconciling | segment assets | at 2023-05-31 | ¥55m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2023-05-31 | −¥255m |
| Cosmetic Drug And Convenience Storereportable segment | capex | 2022-06-01 → 2023-05-31 | ¥4m |
| Cosmetic Drug And Convenience Storereportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥44m |
| Cosmetic Drug And Convenience Storereportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥7.8bn |
| Cosmetic Drug And Convenience Storereportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥7.8bn |
| Cosmetic Drug And Convenience Storereportable segment | segment assets | at 2023-05-31 | ¥1.9bn |
| Cosmetic Drug And Convenience Storereportable segment | segment profit | 2022-06-01 → 2023-05-31 | −¥199m |
| Custody Of Medical Documentsreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥8m |
| Custody Of Medical Documentsreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥42m |
| Custody Of Medical Documentsreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥646m |
| Custody Of Medical Documentsreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥646m |
| Custody Of Medical Documentsreportable segment | segment assets | at 2023-05-31 | ¥1.8bn |
| Custody Of Medical Documentsreportable segment | segment profit | 2022-06-01 → 2023-05-31 | ¥81m |
| Dispensing Pharmacyreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥476m |
| Dispensing Pharmacyreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥425m |
| Dispensing Pharmacyreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥42.3bn |
| Dispensing Pharmacyreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥42.3bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2023-05-31 | ¥17.5bn |
| Dispensing Pharmacyreportable segment | segment profit | 2022-06-01 → 2023-05-31 | ¥1.7bn |
| Medical Mallreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥0 |
| Medical Mallreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥34m |
| Medical Mallreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥505m |
| Medical Mallreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥505m |
| Medical Mallreportable segment | segment assets | at 2023-05-31 | ¥199m |
| Medical Mallreportable segment | segment profit | 2022-06-01 → 2023-05-31 | ¥90m |
| —segment total | capex | 2022-06-01 → 2023-05-31 | ¥489m |
| —segment total | depreciation | 2022-06-01 → 2023-05-31 | ¥547m |
| —segment total | revenue | 2022-06-01 → 2023-05-31 | ¥51.3bn |
| —segment total | revenue external | 2022-06-01 → 2023-05-31 | ¥51.3bn |
| —segment total | segment assets | at 2023-05-31 | ¥21.4bn |
| —segment total | segment profit | 2022-06-01 → 2023-05-31 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-06-01 → 2023-05-31 | ¥598m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-06-01 → 2023-05-31 | ¥589m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-06-01 → 2023-05-31 | ¥52.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-06-01 → 2023-05-31 | ¥52.0bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-05-31 | ¥23.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-06-01 → 2023-05-31 | ¥1.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,628
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)太陽有限責任監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)田 尻 慶 太 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)篠 田 友 彦 | |
| Key audit matters consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)ファーマライズ株式会社の調剤薬局事業及び物販事業における店舗固定資産の減損 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)連結財務諸表注記（重要な会計上の見積り） | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information consolidated (text) | FilingDateInstant | Text · Plus | |
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)太陽有限責任監査法人 | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)田 尻 慶 太 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)篠 田 友 彦 | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior4YearDuration | 51030000000 | JPY |
| Net sales (5-year summary) | Prior3YearDuration | 52324000000 | JPY |
| Net sales (5-year summary) | Prior2YearDuration | 51608000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 52030000000 | JPY |
| Net sales (5-year summary) | CurrentYearDuration | 54466000000 | JPY |
| Ordinary income loss (5-year summary) | Prior4YearDuration | 1023000000 | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration | 1288000000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration | 1517000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 1431000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration | 833000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior4YearDuration | 577000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior3YearDuration | 426000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior2YearDuration | 447000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 333000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYearDuration | -351000000 | JPY |
| Comprehensive income (5-year summary) | Prior4YearDuration | 580000000 | JPY |
| Comprehensive income (5-year summary) | Prior3YearDuration | 414000000 | JPY |
| Comprehensive income (5-year summary) | Prior2YearDuration | 453000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 372000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYearDuration | -325000000 | JPY |
| Net assets (5-year summary) | Prior4YearInstant | 5946000000 | JPY |
| Net assets (5-year summary) | Prior3YearInstant | 6331000000 | JPY |
| Net assets (5-year summary) | Prior2YearInstant | 6699000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 6987000000 | JPY |
| Net assets (5-year summary) | CurrentYearInstant | 7442000000 | JPY |
| Total assets (5-year summary) | Prior4YearInstant | 25206000000 | JPY |
| Total assets (5-year summary) | Prior3YearInstant | 24724000000 | JPY |
| Total assets (5-year summary) | Prior2YearInstant | 23746000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 23421000000 | JPY |
| Total assets (5-year summary) | CurrentYearInstant | 29486000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |